[go: up one dir, main page]

WO2019159005A3 - Method of treating pain comprising repeated administrations of tetrodotoxin over time - Google Patents

Method of treating pain comprising repeated administrations of tetrodotoxin over time Download PDF

Info

Publication number
WO2019159005A3
WO2019159005A3 PCT/IB2019/000164 IB2019000164W WO2019159005A3 WO 2019159005 A3 WO2019159005 A3 WO 2019159005A3 IB 2019000164 W IB2019000164 W IB 2019000164W WO 2019159005 A3 WO2019159005 A3 WO 2019159005A3
Authority
WO
WIPO (PCT)
Prior art keywords
tetrodotoxin
treating pain
over time
repeated administrations
subsequent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2019/000164
Other languages
French (fr)
Other versions
WO2019159005A2 (en
Inventor
Donald C.k. WONG
Walter N. KORZ
Christopher C. Gallen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wex Pharmaceuticals Inc
Original Assignee
Wex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wex Pharmaceuticals Inc filed Critical Wex Pharmaceuticals Inc
Publication of WO2019159005A2 publication Critical patent/WO2019159005A2/en
Publication of WO2019159005A3 publication Critical patent/WO2019159005A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of treating pain comprising an initial administration of tetrodotoxin followed by subsequent administrations after a period of time to maintain analgesia. Both the initial administration and subsequent administration of tetrodotoxin may be carried out over multiple days, with dosing taking place multiple times each day. The initial and subsequent administrations may use the same or different routes. Additional pharmaceutically active ingredients may also be included in the subsequent administrations of tetrodotoxin.
PCT/IB2019/000164 2018-02-15 2019-02-15 Tetrodotoxin multidose methods of treatment Ceased WO2019159005A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862631088P 2018-02-15 2018-02-15
US62/631,088 2018-02-15
US201962802762P 2019-02-08 2019-02-08
US62/802,762 2019-02-08

Publications (2)

Publication Number Publication Date
WO2019159005A2 WO2019159005A2 (en) 2019-08-22
WO2019159005A3 true WO2019159005A3 (en) 2019-09-26

Family

ID=67619842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/000164 Ceased WO2019159005A2 (en) 2018-02-15 2019-02-15 Tetrodotoxin multidose methods of treatment

Country Status (1)

Country Link
WO (1) WO2019159005A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097358A2 (en) * 2005-03-18 2006-09-21 Wex Pharmaceuticals, Inc. Analgesic combination of sodium channel blockers with opioid antagonists
WO2007025212A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
WO2007025213A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the management of musculoskeletal pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097358A2 (en) * 2005-03-18 2006-09-21 Wex Pharmaceuticals, Inc. Analgesic combination of sodium channel blockers with opioid antagonists
WO2007025212A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
WO2007025213A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the management of musculoskeletal pain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAGEN ET AL., CURRENT ONCOLOGY, vol. 18, no. 3, 2011, pages e110 - e116 *
HAGEN ET AL.: "Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial", PAIN RESEARCH AND MANAGEMENT, vol. 2017, 7212713, 7 May 2017 (2017-05-07), XP055636697 *

Also Published As

Publication number Publication date
WO2019159005A2 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2025000166A (en) A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CA3188924A1 (en) Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
WO2018106108A8 (en) Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain
MX2020007625A (en) Mtor inhibitor, pharmaceutical composition and use thereof.
EP4596543A3 (en) Farnesoid x receptor agonists and uses thereof
MX2023010064A (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof.
CA3010829A1 (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
MX2022006533A (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
GEP20247585B (en) Furoindazole derivatives
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
AU2017312811A8 (en) Liquid naloxone spray
EP3992194A4 (en) Benzodiazepine compound, preparation method therefor, and use thereof in medicine
WO2020243273A3 (en) Methods of treating cholangiocarcinoma
AU2017370226A1 (en) Pharmaceutical composition containing insulin-like growth factor-2 and use thereof
WO2019159005A3 (en) Method of treating pain comprising repeated administrations of tetrodotoxin over time
GEP20227384B (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment
MX2020008129A (en) Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof.
WO2019126695A3 (en) Methods and pharmaceutical compositions for treating candida auris in blood
EP3842808A4 (en) Administration managing apparatus, administration managing method and program
CR20200616A (en) Methods of modulating tetrabenazine metabolites plasma levels using bupropion
EP4578505A3 (en) Ketamine composition for use in a method of treatment of depression by pulmonary administration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19753741

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19753741

Country of ref document: EP

Kind code of ref document: A2